Comparing two forms of abiraterone for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether a new version of the drug abiraterone (abiraterone acetate II) works as well as the standard version for men with metastatic castration-resistant prostate cancer (MCRPC) that has progressed. You may qualify if you have already had one type of hormone therapy or chemotherapy and your cancer is spreading.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man 18 years or older.
- Your cancer is prostate adenocarcinoma (not a rare type like neuroendocrine or small cell cancer).
- You are on hormone therapy (like Lupron) or had your testicles removed, and your testosterone is at castration levels.
- Your cancer has gotten worse despite hormone therapy, shown by rising PSA, new tumors, or new bone lesions.
- You have had only one prior treatment for hormone-sensitive prostate cancer (like enzalutamide or docetaxel) and no abiraterone before.
- Your blood counts and organ function are within safe limits, and you have no active infections or heart problems.
- You do not have untreated brain metastases or severe bone problems from cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, TY-302, combined with abiraterone (a standard hormone therapy) for men with metastatic castration-resistant prostate cancer that has stopped responding to one prior new hormone therapy. The goal is to see if the combination can help control the disease.
This trial tests a new drug, HRS-4357, against standard treatments for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see if the new drug works better.
This study is comparing two drugs, abiraterone and darolutamide, to see how well they work for advanced prostate cancer. You might join if your cancer has spread and your doctor agrees these treatments could help.
This trial tests a new medicine (BMS-986365) against the doctor's choice of standard therapy for men with metastatic castration-resistant prostate cancer. It aims to see which treatment works better and is safer.
This trial tests a new combination of two study drugs (HRS-1167 and abiraterone with prednisone) for men with prostate cancer that has spread beyond the prostate. The goal is to see if the combination works better than current treatments.
This trial compares a personalized (adaptive) treatment plan versus a steady (continuous) plan using either abiraterone or enzalutamide (with the same standard hormone-suppression). It aims to see which approach controls advanced metastatic prostate cancer better while keeping side effects manageable.
Hear when a new Abiraterone Acetate trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.